Albuminuria as early test for vascular disease

Lancet

Volumn 365, Issue 9459, 2005, Pages 556-557

  Remuzzi, Giuseppe ^a   Weening, Jan J ^b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DEVELOPING COUNTRY; DISEASE COURSE; EUROPE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SCREENING TEST; VACCINATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 13844275419     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)70775-3     Document Type: Note

References (12)

1. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 12:2001;2753-2758
2. Wild SH, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030: response to Rathman and Giani. Diabetes Care. 27:2004;2569-2570
3. Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant. 17:2002;2071-2076
4. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 13:(suppl 1):2002;S37-40
5. Barsoum RS. Overview: end-stage renal disease in the developing world. Artif Organs. 26:2002;737-746
6. Brenner BM. Retarding the progression of renal disease. Kidney Int. 64:2003;370-378
7. Brenner BM, Zagrobelny J. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney Int Suppl 2003; Feb: S77-85.
8. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1997;1857-1863
9. Brenner BM, Cooper ME, de Zeeuw D, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-69.
10. Hillege HL, Fidler V, Diercks GF, for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
11. Ruggenenti P, Fassi A, Ilieva AP, for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.
12. Verhave JC, Gansevoort RT, Hillege HL, for the PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; Nov: S18-21.